相关临床试验
96
17 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1966
进行中（未招募）
9
9.4%
已完成
56
58.3%
尚未招募
8
8.3%
招募中
15
15.6%
Unknown
7
7.3%
撤回
1
1.0%
暂无批准数据
- Researchers from the University of Bath and UMass Chan Medical School have identified a molecular navigation system that precisely directs neutrophils to infection sites without damaging healthy tissues. - The study, published in Science Advances, reveals that the TRPV2/CB2R receptor complex acts as an accelerator-brake system, with infected cells releasing hepoxilin A₃ to guide neutrophil migration. - Current anti-inflammatory drugs broadly suppress inflammation throughout the body, causing side effects; this discovery offers a pathway to target inflammation only when and where it occurs. - The research team plans to investigate blocking the hepoxilin A₃ signal pathway as a potential new class of anti-inflammatory drug molecules for chronic gut and lung diseases.
- Revolver Therapeutics, a University of Bath spinout, has raised £572,000 in a funding round led by QantX with follow-on investment from UKI2S and the University of Bath. - The company is developing cell-penetrating peptides designed to shut down transcription factors, master regulators of disease long considered "undruggable" by conventional small-molecule drugs. - The proprietary Transcription Block Survival platform enables discovery of peptides that enter cells and switch off these previously unreachable targets, overcoming a decades-old barrier in drug development. - The new capital will advance Revolver's platform and pipeline, with an initial focus on colorectal cancers with significant unmet medical needs.
- The Medical Research Council (MRC) is investing £9.7 million to establish ten Regional Accounts for Clinical Researchers (RACR) across the UK. - The initiative brings together more than 50 research organisations and over 60 NHS organisations across England, Scotland, Wales and Northern Ireland. - The programme will deliver flexible, tailored support to more than 190 clinicians at critical career "pinch points" over the next two years. - The University of Exeter and Royal Devon University Healthcare NHS Foundation Trust will join the Great Western Clinical Research Alliance to support clinical academics.
- Moderna has partnered with Korea University College of Medicine since 2023 to develop an experimental mRNA-based hantavirus vaccine targeting multiple strains of the deadly virus. - The U.S. Army has completed Phase 1 clinical trials for DNA vaccines against three hantavirus strains, including the Andes virus responsible for the recent cruise ship outbreak. - The Andes virus strain has a fatality rate of 30-50% and is the only hantavirus known to spread between humans, making vaccine development critically important. - Researchers are exploring innovative delivery methods including "ensilication" technology that could enable drone delivery of vaccines to remote areas.
- Clean Food Group acquired Algal Omega 3's one million-liter fermentation facility in Liverpool, positioning itself as the world's largest manufacturer of yeast fermentation-derived sustainable oils and fats. - The acquisition enables commercial-scale production without costly new infrastructure, with CFG already validating the process by manufacturing two tons of oil in a recent fermentation run. - The company received regulatory approval for its CLEAN Oil™ 25 product in cosmetics markets across the UK, Europe, and US, with food applications pending regulatory review. - CFG targets the $20 billion sustainable oils market, offering alternatives to tropical and animal fats for food, cosmetics, and pet food industries through its proprietary yeast fermentation technology.
- Bristol-based biotech EnsiliTech secured £4.5 million in oversubscribed seed funding to advance its Ensilication technology that makes vaccines and biologics stable at room temperature. - The patented technology uses silica coatings to preserve biopharmaceuticals at temperatures up to 50°C, potentially eliminating the need for expensive cold chain storage systems. - Cold chain failures currently cost the pharmaceutical industry an estimated £26 billion annually, with up to 50% of vaccines wasted in developing economies due to refrigeration breakdowns. - The funding will accelerate proof-of-concept development and generate validation data needed to integrate Ensilication into pharmaceutical manufacturing workflows.
- Researchers at the University of Bath have developed a breakthrough technology that enables oral delivery of protein-based drugs like growth hormone and monoclonal antibodies that traditionally require injection. - The system uses a bacterial-derived carrier molecule that exploits natural intestinal transport mechanisms to deliver therapeutic proteins across the gut wall with 5-10% bioavailability. - The technology could transform treatment for chronic conditions requiring frequent injections, with human testing projected to begin within two years. - The platform safely transports various protein therapeutics including hormones and cancer treatments without damaging intestinal tissue or causing inflammation.
- A three-minute Fastball EEG test successfully identified memory problems linked to Alzheimer's disease in people with mild cognitive impairment before typical diagnosis occurs. - The trial involving 106 participants found that those with amnestic MCI showed reduced brain responses compared to healthy adults, indicating higher Alzheimer's risk. - Cumulus Neuroscience is launching a 1,000-subject study to further validate the at-home EEG headset technology for early Alzheimer's detection. - The passive test could help identify patients who would benefit most from new Alzheimer's drugs like donanemab and lecanemab when treatment is most effective.
